Evidence map›Paper›PMID 38026733›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2023

Bridging the Gap: Exploring the Preclinical Potential of

Edilson Rodrigues Albuquerque, Gustavo Ratti da Silva, Fernanda de Abreu Braga, Ester Pelegrini Silva, Karina Sposito Negrini, Julia Amanda Rodrigues Fracasso, Lucas Pires Guarnier, Ezilda Jacomassi, João Tadeu Ribeiro-Paes, Roberto da Silva Gomes and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Unveiling the Phytochemical Diversity ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  2. Effects ofPharmaceutics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Edilson Rodrigues AlbuquerqueLaboratory of Preclinical Research of Natural Products, Post Graduate Program in Animal Science with Emphasis on Bioactive Products, Universidade Paranaense, Umuarama, Brazil.ORCID https://orcid.org/0000-0001-5773-9912
Gustavo Ratti da SilvaLaboratory of Preclinical Research of Natural Products, Post Graduate Program in Animal Science with Emphasis on Bioactive Products, Universidade Paranaense, Umuarama, Brazil.ORCID https://orcid.org/0000-0001-7224-8898
Fernanda de Abreu BragaLaboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil.ORCID https://orcid.org/0000-0003-2398-800X
Ester Pelegrini SilvaLaboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil.ORCID https://orcid.org/0000-0002-2197-239X
Karina Sposito NegriniLaboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil.ORCID https://orcid.org/0000-0002-7294-7469
Julia Amanda Rodrigues FracassoSchool of Dentistry, São Paulo State University, Araçatuba, Brazil.ORCID https://orcid.org/0000-0003-3553-534X
Lucas Pires GuarnierDepartment of Genetic, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-0733-1975
Ezilda JacomassiLaboratory of Preclinical Research of Natural Products, Post Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, Brazil.ORCID https://orcid.org/0000-0003-0967-8427
João Tadeu Ribeiro-PaesDepartment of Biotechnology, São Paulo State University, Assis, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-7645-5891
Roberto da Silva GomesDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota 58102, USA.ORCID https://orcid.org/0000-0002-8075-9716
Arquimedes Gasparotto JuniorLaboratory of Cardiovascular Pharmacology, Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, Brazil.ORCID https://orcid.org/0000-0003-3433-5098
Francislaine Aparecida Dos Reis LíveroLaboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil.ORCID https://orcid.org/0000-0001-6533-0850

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic-associated fatty liver disease (MAFLD) is a complex condition characterized by steatosis and metabolic disturbances. Risk factors such as diabetes, cigarette smoking, and dyslipidaemia contribute to its development and progression. Effective and safe therapies for MAFLD are urgently needed.

Identifiers

PMID38026733
PMCPMC10653969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.